Simon Ball
Barking, Havering And Redbridge University Hospitals NHS Trust · 10 works · 604 citations · h-index 4
Top works
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
- OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
- 375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC
- Is the Management of Rectal Cancer Using a Watch and Wait Approach Feasible, Safe and Effective in a Publicly Funded General Hospital?
- Utility of T790M plasma and tissue biopsy testing in EGFR mutated non-small-cell lung cancer patients
- Outcomes of Watch and Wait (WW) in rectal cancer patients - largest single centre series in United Kingdom
- Overall survival of stage III non-small cell lung cancer (NSCLC) in patients with good performance status at Barking, Havering & Redbridge University Hospitals NHS Trust (BHRUT)
- Estimating renal function in lung cancer patients
- High rates of radical treatment for stage III non-small cell lung cancer (NSCLC) at Barking, Havering & Redbridge University Hospitals NHS Trust (BHRUT)
- Is management of rectal cancer using watch-and-wait approach feasible, safe, and effective in a publicly funded general hospital?